<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Institute of Hepatology</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E23E0565-674D-4DAF-AABD-026669ACF3E0"><gtr:id>E23E0565-674D-4DAF-AABD-026669ACF3E0</gtr:id><gtr:firstName>Kevin</gtr:firstName><gtr:otherNames>Peter</gtr:otherNames><gtr:surname>Moore</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/9DC89644-D4F0-48A7-84C3-4A725628BFA8"><gtr:id>9DC89644-D4F0-48A7-84C3-4A725628BFA8</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:surname>Burroughs</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0800971"><gtr:id>1BF39E5B-FE51-4F77-9E09-5CB152C1DF52</gtr:id><gtr:title>Characterising the D-Galactosamine Rat Model of Hepatorenal Syndrome</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0800971</gtr:grantReference><gtr:abstractText>Patients with liver failure, caused by virus infection, alcohol or their daily medicines often develop acute kidney failure (hepatorenal syndrome). We are not sure how or why this occurs, but it is caused by a marked decrease of blood flow to the kidneys, itself caused by a reduction in the effectiveness of the heart to beat blood around the body, an opening up of blood vessels that supply the intestines, and increased production of a series of compounds which reduce kidney blood flow further. We appear to have a good animal model of this syndrome, but it needs further characterisation and direct comparison to patients with acute or acute on chronic liver failure who develop the hepatorenal syndrome. The aim of this study is to test the hypothesis that this animal model of acute liver and kidney failure is representative of the human disease. The second part of the study will determine some mechanisms by which we can improve kidney function in this animal model and hopefully use to treat patients with the hepatorenal syndrome.</gtr:abstractText><gtr:technicalSummary>The hepatorenal syndrome, in which renal failure develops secondary to severe liver disease is a common complication of acute liver failure or acute on chronic liver failure. The D-galactosamine model of acute liver and renal failure appears to be an ideal model for this syndrome, sharing many of its essential chracteristics including renal vasoconstriction, normal renal histology and functional renal failure. However, its characteristics need to be fully identified and compared to those which occur in patients with acute liver failure or acute on chronic liver failure and and the hepatorenal syndrome. Importantly, it has recently been shown that patients developing HRS have impaired cardiovascular responses to physiological stimuli and thus insufficent cardiac output during stress. This, together with systemic vasodilatation, causes a reduction of blood pressure and a marked reduction of renal blood flow, which is key to the development of hepatorenal syndrome. We and others have observed similar findings (i.e. a decrease in effective cardiac responses) in a rat model of cirrhosis, and this is associated with increased nitration of cardiac proteins. Both impaired cardiac function and nitration of cardiac proteins is reversed by treatment with N-acetylcysteine, a drug we have previously shown to improve renal function in patients with early hepatorenal syndrome. This study will characterise the D-galactosamine model of acute liver and renal failure, comparing and contrasting it, where possible, to patients who develop hepatorenal syndrome or historical studies. We will use this model to dissect some of the key mechanisms by which N-acetylcysteine and possibly other drugs improve kidney function in the hepatorenal syndrome.</gtr:technicalSummary><gtr:fund><gtr:end>2011-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>407421</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have developed a robust and highly sensitive assasy for the measurement of hydrogen sulphide in plasma</gtr:description><gtr:id>C5567A48-AEE4-42D0-8BF4-45E3E24E6B08</gtr:id><gtr:impact>This may help to teh development of a new drug for sepsis and multi-organ failure</gtr:impact><gtr:outcomeId>kBLpwnTQoMR</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Measurement of hydrogen sulphide</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have discovered that as rats go from 4 weeks to 5 weeks post bile duct ligation that they deveop impaired cardiac function in eth same way as humans do who develop hepatorenal syndrome.</gtr:description><gtr:id>3E2E02E2-9C75-4602-86F0-027E32D68FF1</gtr:id><gtr:impact>This will help us understand somne of the mechanisms leading to hepatorenal syndrome.</gtr:impact><gtr:outcomeId>D9r5DFUvdzM</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Impaired cardiac output with advanced cirrhosis</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>02D5B2CC-AE80-4056-B6C3-3A2ABA690FD7</gtr:id><gtr:title>Decreased heart rate variability in patients with cirrhosis relates to the presence and degree of hepatic encephalopathy.</gtr:title><gtr:parentPublicationTitle>American journal of physiology. Gastrointestinal and liver physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/319f81d0ff011a306921fd24d50a2128"><gtr:id>319f81d0ff011a306921fd24d50a2128</gtr:id><gtr:otherNames>Mani AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0193-1857</gtr:issn><gtr:outcomeId>NWbV7zkU31A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4F077FD-28E0-44FA-8664-84C2685C93DB</gtr:id><gtr:title>Myocardial stunning is associated with impaired calcium uptake by sarcoplasmic reticulum.</gtr:title><gtr:parentPublicationTitle>Biochemical and biophysical research communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/22e459c4c42360108e16cea2f07aec37"><gtr:id>22e459c4c42360108e16cea2f07aec37</gtr:id><gtr:otherNames>Kumar S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-291X</gtr:issn><gtr:outcomeId>YsJ7Jj7aozm</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8F0EBC0C-136F-41A6-98F5-06D17D807F56</gtr:id><gtr:title>Nitric oxide-dependent bradycardia in mutant analbuminemic rats.</gtr:title><gtr:parentPublicationTitle>Biochemical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/319f81d0ff011a306921fd24d50a2128"><gtr:id>319f81d0ff011a306921fd24d50a2128</gtr:id><gtr:otherNames>Mani AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-2952</gtr:issn><gtr:outcomeId>pm_16556_26_22889827</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B6B880F5-05CE-4E86-B5D2-84F70C582902</gtr:id><gtr:title>d-Serine modulates neurogenic relaxation in rat corpus cavernosum.</gtr:title><gtr:parentPublicationTitle>Biochemical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/abc9b049465d677335beb8486fca9848"><gtr:id>abc9b049465d677335beb8486fca9848</gtr:id><gtr:otherNames>Ghasemi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-2952</gtr:issn><gtr:outcomeId>MUy726pY4y5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0ECB2C63-2239-4F3B-8ED9-73CC30B58443</gtr:id><gtr:title>Measuring reactive oxygen and nitrogen species with fluorescent probes: challenges and limitations.</gtr:title><gtr:parentPublicationTitle>Free radical biology &amp; medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d9cc82d66651325e3db5bddb5510965b"><gtr:id>d9cc82d66651325e3db5bddb5510965b</gtr:id><gtr:otherNames>Kalyanaraman B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0891-5849</gtr:issn><gtr:outcomeId>Bqm4iAzADWA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F724E5B-6382-4547-B77A-CFD22602CAD8</gtr:id><gtr:title>Endotoxemia is associated with partial uncoupling of cardiac pacemaker from cholinergic neural control in rats.</gtr:title><gtr:parentPublicationTitle>Shock (Augusta, Ga.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ebe2aab8fcb670b88d1562d85223bc8"><gtr:id>4ebe2aab8fcb670b88d1562d85223bc8</gtr:id><gtr:otherNames>Gholami M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1073-2322</gtr:issn><gtr:outcomeId>pm_16556_26_22249221</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>066560FE-1468-4A7F-A539-E2485C838CF2</gtr:id><gtr:title>Acetaminophen inhibits hemoprotein-catalyzed lipid peroxidation and attenuates rhabdomyolysis-induced renal failure.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/96a50d89421c6f16a575850af78ab992"><gtr:id>96a50d89421c6f16a575850af78ab992</gtr:id><gtr:otherNames>Boutaud O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>g8oPBiEXBtT</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>25A0015A-7530-4379-B90B-AF6DC6E7CA34</gtr:id><gtr:title>New insights into the role of endogenous opioids in the pathogenesis of gastrointestinal and liver disease.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/319f81d0ff011a306921fd24d50a2128"><gtr:id>319f81d0ff011a306921fd24d50a2128</gtr:id><gtr:otherNames>Mani AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>9BC7F560E67</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B6EF69F-19D8-4C6A-8BA4-7168DC142071</gtr:id><gtr:title>Making and working with hydrogen sulfide: The chemistry and generation of hydrogen sulfide in vitro and its measurement in vivo: a review.</gtr:title><gtr:parentPublicationTitle>Free radical biology &amp; medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/591d4a65c7b7de1d8cdfca18d5a64f01"><gtr:id>591d4a65c7b7de1d8cdfca18d5a64f01</gtr:id><gtr:otherNames>Hughes MN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0891-5849</gtr:issn><gtr:outcomeId>425310CD7F4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>505DB553-073C-4798-8B91-4D03C66FB1C1</gtr:id><gtr:title>Role of endogenous hydrogen sulfide in neurogenic relaxation of rat corpus cavernosum.</gtr:title><gtr:parentPublicationTitle>Biochemical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/abc9b049465d677335beb8486fca9848"><gtr:id>abc9b049465d677335beb8486fca9848</gtr:id><gtr:otherNames>Ghasemi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-2952</gtr:issn><gtr:outcomeId>pm_16556_26_22306852</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800971</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>10</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>D81A471F-556F-4570-BF6A-5D197943223C</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Oral and Gastrointestinal</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>2EEE0958-6BE1-4D16-B86B-5D954CD37219</gtr:id><gtr:percentage>40</gtr:percentage><gtr:text>Renal and Urogenital</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>CDB856E6-DF2D-4D96-88BD-1CC96FE277EF</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.2  Factors relating to physical environment</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>